All In Biotech

Drug Trial Radar · NCT06619990

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of XmAb942 in Participants With Moderate-To-Severe Active Ulcerative Colitis.

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Oct 10, 2024

Primary completion

Dec 2027

Study completion May 2030

Sponsor

Lead sponsor
Xencor, Inc.Industry
Sponsor type
Industry
First posted
Oct 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • XmAb942Biological

    Antibody

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of XmAb942 in healthy volunteers (Part A)Time frame: 20 weeks
  2. Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of XmAb942 in healthy volunteers (Part B)Time frame: 28 weeks
  3. Clinical remission based on modified mayo score (MMS), defined as MMS ≤ 2 with Mayo endoscopic score (MES) of 1, rectal bleeding subscore (RBS) of 0, and stool frequency subscore (SFS) of 0-1.Time frame: 12 weeks

Locations

114 sites in 19 countries. Site status is shown where the registry gives one.

  • Xencor Investigative Site

    Scottsdale, Arizona · Recruiting

  • Xencor Investigative Site

    Palo Alto, California · Recruiting

  • Xencor Investigative Site

    Bradenton, Florida · Recruiting

  • Xencor Investigative Site

    Brandon, Florida · Recruiting

  • Xencor Investigative Site

    Jacksonville, Florida · Recruiting

  • Xencor Investigative Site

    Kissimmee, Florida · Recruiting

  • Xencor Investigative Site

    Margate, Florida · Recruiting

  • Xencor Investigative Site

    Palmetto Bay, Florida · Recruiting

  • Xencor Investigative Site

    Tampa, Florida · Recruiting

  • Xencor Investigative Site

    Tampa, Florida · Recruiting

  • Xencor Investigative Site

    Tampa, Florida · Recruiting

  • Xencor Investigative Site

    Louisville, Kentucky · Recruiting

  • Xencor Investigative Site

    Oxford, Mississippi · Recruiting

  • Xencor Investigative Site

    Tupelo, Mississippi · Recruiting

  • Xencor Investigative Site

    Albany, New York · Recruiting

  • Xencor Investigative Site

    Rochester, New York · Recruiting

  • Xencor Investigative Site

    Raleigh, North Carolina · Recruiting

  • Xencor Investigative Site

    Beavercreek, Ohio · Recruiting

  • Xencor Investigative Site

    Cordova, Tennessee · Recruiting

  • Xencor Investigative Site

    Cedar Park, Texas · Recruiting

  • Xencor Investigative Site

    Denton, Texas · Recruiting

  • Xencor Investigative Site

    Garland, Texas · Recruiting

  • Xencor Investigative Site

    Georgetown, Texas · Recruiting

  • Xencor Investigative Site

    Houston, Texas · Recruiting

  • Xencor Investigative Site

    Houston, Texas · Recruiting

  • Xencor Investigative Site

    Kingwood, Texas · Recruiting

  • Xencor Investigative Site

    Lubbock, Texas · Recruiting

  • Xencor Investigative Site

    San Antonio, Texas · Recruiting

  • Xencor Investigative Site

    Tyler, Texas · Recruiting

  • Xencor Investigative Site

    Webster, Texas · Recruiting

  • Xencor Investigative Site

    Richmond, Virginia · Recruiting

  • Xencor Investigative Site

    Buenos Aires, Argentina · Recruiting

  • Xencor Investigative Site

    Buenos Aires, Argentina · Recruiting

  • Xencor Investigative Site

    Buenos Aires, Argentina · Recruiting

  • Xencor Investigative Site

    Rosario, Argentina · Recruiting

  • Xencor Investigative Site

    San Miguel de Tucumán, Argentina · Recruiting

  • Xencor Investigative Site

    Adelaide, Australia · Recruiting

  • Xencor Investigative Site

    Brisbane, Australia · Recruiting

  • Xencor Investigative Site

    Joondalup, Australia · Completed

  • Xencor Investigative Site

    Macquarie Park, Australia · Recruiting

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.